Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.5705
+0.2229 (64.13%)
At close: Mar 28, 2025, 4:00 PM
0.5805
+0.0100 (1.75%)
After-hours: Mar 28, 2025, 4:39 PM EDT
Lexicon Pharmaceuticals Stock Forecast
LXRX's stock price has decreased by -73.95% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Lexicon Pharmaceuticals stock have an average target of 3.67, with a low estimate of 1.00 and a high estimate of 6.00. The average target predicts an increase of 543.30% from the current stock price of 0.57.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +601.14% | Mar 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +951.71% | Mar 7, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +601.14% | Mar 7, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $1 | Buy → Hold | Downgrades | $1 | +75.28% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
13.60M
from 31.08M
Decreased by -56.24%
Revenue Next Year
27.46M
from 13.60M
Increased by 101.91%
EPS This Year
-0.39
from -0.63
EPS Next Year
-0.34
from -0.39
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.0M | 88.3M | 185.6M | ||
| Avg | 13.6M | 27.5M | 76.4M | ||
| Low | 4.8M | 3.0M | 1.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.7% | 549.5% | 575.9% | ||
| Avg | -56.2% | 101.9% | 178.3% | ||
| Low | -84.6% | -77.7% | -93.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.37 | -0.21 | -0.11 | ||
| Avg | -0.39 | -0.34 | -0.30 | ||
| Low | -0.39 | -0.46 | -0.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.